Multiple Sclerosis
2,553
312
417
1,424
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
323 trials with published results (13%)
Research Maturity
1424 completed trials (56% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.6%
142 terminated out of 2553 trials
90.9%
+4.4% vs benchmark
11%
273 trials in Phase 3/4
23%
323 of 1424 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1424 completed trials
Clinical Trials (2553)
Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
The Effect of DNS-Based Training Combined With PFMT on LUTS and Pelvic Floor Functions in Women With MS
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Conventional Vestibular Training Versus Immersive Virtual Reality- Based Vestibular in Multiple Sclerosis
Mixed Reality for Upper Limb Rehabilitation in People With Multiple Sclerosis (VIRTUALDOMUS)
Physical Telerehabilitation in Veterans With Multiple Sclerosis
Care in Multiple Sclerosis (MS)
ECoG BMI for Motor and Speech Control
Effectiveness of Home-Based Exercise and Brain Stimulation for Reducing Fatigue in Patients With Multiple Sclerosis
Augmented Reality-Based Dual-Task Training in People With Multiple Sclerosis
Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
Phenotypic and Functional Study of 4BL B Cells in Multiple Sclerosis (MS)
Deployment o the Multidisciplinary Prospective Cohort Imminent
MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis
A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
Nutritional Status and Muscle Function in Ambulatory Multiple Sclerosis Patients With Dysphagia
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?